Cholangiocarcinoma

Oncology·MeSH: Cholangiocarcinoma

Prevalence

2.5 / 100K

Incidence

1.3 / 100K/yr

23 drugs in development·19 companies·33 clinical trials

Drug Pipeline by Phase

Phase 3(10)

Drug	Company
CGT4859	Cogent Biosciences, Inc. (COGT)
derazantinib	ARQULE INC (ARQL)
FOLFIRI or FOLFOX or Regorafenib	IGM Biosciences, Inc. (IGMS)
hmpl-453	HUTCHMED (China) Limited (HCM)
hmpl-453	HUTCHMED (China) Ltd (HMDCF)
Ivosidenib	AGIOS PHARMACEUTICALS, INC. (AGIO)
Ivosidenib Oral Tablet	AGIOS PHARMACEUTICALS, INC. (AGIO)
pemigatinib	Incyte Corp. (INCY)
renovogem	RenovoRx, Inc. (RNXT)
truseltiq	BridgeBio Pharma, Inc. (BBIO)

Phase 2(8)

Drug	Company
abc294640	RedHill Biopharma Ltd. (RDHL)
AG-120	AGIOS PHARMACEUTICALS, INC. (AGIO)
certepetide	LISATA THERAPEUTICS, INC. (LSTA)
folfox regimen	LISATA THERAPEUTICS, INC. (LSTA)
lsta1	LISATA THERAPEUTICS, INC. (LSTA)
PD-1antibody plus GEMOX	Merus N.V. (MRUS)
tas-120	CG Oncology, Inc. (CGON)
vg2025	IO Biotech, Inc. (IOBT)

Phase 1(4)

Drug	Company
Entinostat	Syndax Pharmaceuticals Inc (SNDX)
Ivosidenib	ENANTA PHARMACEUTICALS INC (ENTA)
ly3410738	ELI LILLY & Co (LLY)
nelitolimod	TriSalus Life Sciences Inc. (TLSI)

Phase 1/Phase 2(1)

Drug	Company
gns561 + trametinib	Genfit S.A. (GNFT)

BioSniper tracks 23 drugs in development for Cholangiocarcinoma across 19 companies.

There are 33 clinical trials targeting Cholangiocarcinoma tracked by BioSniper.

The estimated prevalence of Cholangiocarcinoma is approximately 2.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.